Table 1.
Baseline Features
| Derivation | Validation | ||
|---|---|---|---|
| Variable | (n=509) | (n=278) | P-value |
| Age (years) | 43.10 (30.10-54.30) | 41.70 (30.60-54.20) | 0.43 |
| Male | 61.70% (314/509) | 69.10% (192/278) | 0.05 |
| PSC Age Diagnosis (years) | 40.00 (27.60-51.40) | 35.30 (26.50-47.20) | 0.02 |
| PSC Duration (years) | 0.49 (0.12-3.06) | 1.44 (0.12-6.18) | <0.01 |
| IBD Present | 80.13% (363/453) | 83.09% (231/278) | 0.10 |
| •Ulcerative colitis | 66.89% (303/453) | 67.60% (188/278) | |
| •Crohn’s disease | 5.74% (26/453) | 10.10% (28/278) | |
| • Indeterminate colitis | 7.51% (34/453) | 5.40% (15/278) | |
| IBD Age Diagnosis | 26.60 (18.30-43.20) | 26.9 0 (16.90-42.00) | 0.46 |
| IBD Duration (years) | 9.69 (2.93-20.80) | 8.44 (1.69-18.40) | 0.42 |
| Platelets × 109/L | 258(220-318) | 273 (215-358) | 0.17 |
| Sodium mmol/L | 140 (138-141) | 140 (139-142) | 0.02 |
| Creatinine mg/dL | 0.90 (0.80-1.10) | 0.8 1 (0.70-0.92) | <0.001 |
| Albumin g/dL | 4.10 (3.70-4.40) | 4. 20 (3.90-4.50) | <0.001 |
| SAP × ULN | 1.82 (1.03-3.41) | 2.05 (1.15-3.50) | 0.26 |
| SAP > 1.5x ULN | 56.20% (213/379) | 62. 27% (148/236) | 0.13 |
| AST U/L | 58 (33-92) | 57 (36- 100) | 0.52 |
| Total Bilirubin mg/dL | 0.80 (0.50-1.30) | 0.80 (0.53 -1.35) | 0.62 |
| MELDa | 7.34 (6.43-8.87) | 7.50 (6.43 -9.36) | 0.15 |
| Mayo PSC Risk Scoreb | −0.09 (−0.71-0.69) | − 0.11 (−0.71-0.59) | 0.39 |
a
Available at baseline (349/509) in derivation and (215/278) in validation cohorts
b
Available at baseline (465/509) in derivation and (246/278) in validation cohorts Continuous variables reported as median (interquartile range)
Abbreviations: PSC (primary sclerosing cholangitis); IBD (inflammatory bowel disease); SAP (serum alkaline phosphatase); ULN (upper limit of normal); AST (aspartate aminotransferase); MELD (model for end-stage liver disease).